Immune Reconstitution Following CD7 CAR-T Therapy for Relapsed/Refractory Acute T-cell Lymphoblastic Leukemia/T-cell Lymphoblastic Lymphoma

Immune Reconstitution Following CD7 CAR-T Therapy for Relapsed/Refractory Acute T-cell Lymphoblastic Leukemia/T-cell Lymphoblastic Lymphoma

From June 13 to 16, 2024, the 29th Annual Congress of the European Hematology Association (EHA) was held in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world every year to share and discuss innovative ideas and the latest scientific and clinical research results in hematology. At this year's EHA meeting, a study (S119) by Professor Xian Zhang from Beijing Lu Daopei Hospital was selected for oral presentation. The study explored immune reconstitution in R/R T-ALL/LBL patients following CD7 CAR-T therapy. “Oncology Frontier - Hematology Frontier” interviewed Professor Xian Zhang to introduce and interpret the study's content and topics related to the treatment of R/R T-ALL/LBL.
EHA in 5 Minutes | Professor Huanling Zhu: SUSTRENIM Trial— Observational Study on Sustained Deep Molecular Response and Treatment-Free Remission

EHA in 5 Minutes | Professor Huanling Zhu: SUSTRENIM Trial— Observational Study on Sustained Deep Molecular Response and Treatment-Free Remission

The 29th Annual Meeting of the European Hematology Association (EHA) was held from June 13-16, 2024, in Madrid, Spain. As the largest international event in the field of hematology in Europe, this conference attracts numerous renowned experts and scholars from around the world to share and discuss innovative concepts, the latest scientific research, and clinical study results in hematology. To gain a deeper understanding of the latest research in Chronic Myeloid Leukemia (CML), "Oncology Frontier - Hematology Frontier" has invited Professor Huanling Zhu from West China Hospital of Sichuan University, to provide an in-depth interpretation.
ASCO 2024丨mRNA-4157 Vaccine Shows Long-Term Survival Benefits in Melanoma Treatment

ASCO 2024丨mRNA-4157 Vaccine Shows Long-Term Survival Benefits in Melanoma Treatment

mRNA cancer vaccines are an emerging cancer treatment strategy that uses mRNA technology to encode tumor-associated antigens, stimulating the patient's immune system to fight cancer cells. With the successful application of mRNA technology in vaccine development, its role in cancer treatment is gaining increasing attention. mRNA-4157 is a novel personalized cancer vaccine that has shown promising efficacy in clinical trials. In the phase II KEYNOTE-942 study, mRNA-4157 combined with pembrolizumab extended relapse-free survival (RFS) for high-risk melanoma patients compared to pembrolizumab alone. At this year's ASCO meeting, the study presented updated 3-year follow-up data. Oncology Frontier has compiled and summarized the findings for our readers.
ASCO 2024丨Impact of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes

ASCO 2024丨Impact of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago from May 31 to June 4. Multiple research advancements in urologic oncology were presented, including the SWOG S1600 study results shared by Dr. Jill Hamilton-Reeves. This study explored the impact of immune-enhancing nutrition on the outcomes of radical cystectomy. Oncology Frontier has compiled and summarized the relevant content for our readers.
JOH | Changes in Liver Stiffness Measurements Independently Associated with Liver-Related Events Risk in NAFLD Patients

JOH | Changes in Liver Stiffness Measurements Independently Associated with Liver-Related Events Risk in NAFLD Patients

Recently, Professor Naga P. Chalasani and his research team from Indiana University published a significant study online in the prestigious hepatology journal JOH. The study, titled "Increases and Decreases in Liver Stiffness Measurements are Independently Associated with the Risk of Liver-Related Events in NAFLD Patients," was initiated by Professor Naga P. Chalasani in collaboration with key researchers in the NAFLD field across the United States, including Professor Arun J. Sanyal from Virginia Commonwealth University. The study aims to provide new insights into disease management and risk assessment for NAFLD patients.
ASCO 2024丨Liver Cancer Research Highlights: First-Line Immunotherapy “Double Star” Post-Immunotherapy Targeted Treatment, and CAR-T Therapy for Liver Cancer

ASCO 2024丨Liver Cancer Research Highlights: First-Line Immunotherapy “Double Star” Post-Immunotherapy Targeted Treatment, and CAR-T Therapy for Liver Cancer

The treatment of advanced hepatocellular carcinoma (HCC) has entered the era of targeted and immunotherapy, with combined regimens becoming the first-line standard. More combination therapies are still under exploration. At the recently concluded 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, the CheckMate 9DW study announced positive results for the dual immunotherapy of anti-PD-L1 and anti-CTLA-4, positioning this "double star" regimen as a potential first-line treatment. Additionally, the conference revealed results from the first Phase II clinical trial of an immune checkpoint inhibitor (ICI) combined with a tyrosine kinase inhibitor (TKI) as a second-line treatment following failure of first-line immunotherapy. Chinese researchers also reported on a Phase I clinical trial of a specific autologous armored-CAR-T cell therapy.
ASCO International Perspective | Christos Kyriakopoulos: Results of the CHAARTED2 Study on Cabazitaxel Combined with Abiraterone for mCRPC

ASCO International Perspective | Christos Kyriakopoulos: Results of the CHAARTED2 Study on Cabazitaxel Combined with Abiraterone for mCRPC

The CHAARTED study demonstrated that early use of chemotherapy combined with androgen deprivation therapy (ADT+docetaxel) significantly improves survival for most patients with metastatic hormone-sensitive prostate cancer (HSPC). However, most patients eventually develop castration-resistant prostate cancer (CRPC) and require additional systemic treatment. At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Professor Christos Kyriakopoulos from the University of Wisconsin Carbone Cancer Center shared the results of the CHAARTED2 clinical study on cabazitaxel combined with abiraterone for metastatic prostate cancer. "Oncology Frontier" interviewed Professor Christos Kyriakopoulos to discuss treatment options for CRPC.
ASCO International Perspective | Professor Jill Hamilton Reeves: Can Enhanced Immunonutrition Improve Outcomes for Radical Cystectomy Patients?

ASCO International Perspective | Professor Jill Hamilton Reeves: Can Enhanced Immunonutrition Improve Outcomes for Radical Cystectomy Patients?

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was held from May 31 to June 4 in Chicago, on the shores of Lake Michigan. Professor Jill Hamilton Reeves from the University of Kansas Medical Center shared the results of the SWOG S1600 study at the conference, exploring the impact of immunonutrition on the outcomes of radical cystectomy (RC). Oncology Frontier  interviewed Professor Jill Hamilton Reeves on-site to discuss the study results.
Immune Checkpoint Expression Patterns on T Cell Subsets in Light-Chain Amyloidosis: VISTA, PD-1, and TIGIT as Potential Therapeutic Targets

Immune Checkpoint Expression Patterns on T Cell Subsets in Light-Chain Amyloidosis: VISTA, PD-1, and TIGIT as Potential Therapeutic Targets

In the dynamic field of hematology and oncology, innovative treatments for systemic amyloid light chain (AL) amyloidosis are essential. Recent research, led by Professor Yangqiu Li from the Institute of Hematology, School of Medicine, Jinan University,, explores immune checkpoint expression patterns in AL amyloidosis. This study investigates VISTA+, PD-1+, Tim-3+, and TIGIT+ T cells in newly diagnosed patients, highlighting the immunosuppressive environment of the disease.The findings reveal the potential of targeting VISTA, PD-1, and TIGIT to reverse T-cell exhaustion, offering new therapeutic avenues.
EHA Expert Interview | Professor Lihua Qiu from Professor Huilai Zhang’s Team Unveils PGI-FL, MCL Research Advances, and New Mechanisms of CD58

EHA Expert Interview | Professor Lihua Qiu from Professor Huilai Zhang’s Team Unveils PGI-FL, MCL Research Advances, and New Mechanisms of CD58

The 29th Annual Meeting of the European Hematology Association (EHA) was held from June 13-16, 2024, in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts numerous renowned experts and scholars each year to share and discuss innovative concepts, the latest scientific research, and clinical study results in hematology. At this year's meeting, several research findings from Professor Huilai Zhang's team at Tianjin Medical University Cancer Institute & Hospital were selected. To gain a deeper understanding of the latest research progress in the field of lymphoma, "Oncology Frontier - Hematology Frontier" has invited Professor Lihua Qiu from the same team for an in-depth interpretation.